Actavis Malta

A Bold New Allergan

Actavis + Allergan

On March 17th, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team.

The Actavis + Allergan Brand portfolio features six blockbuster franchises in key therapeutic categories, including Dermatology and Aesthetics; CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular and Infectious Disease. Supporting these blockbuster franchises is the company’s industry-leading specialty and primary care U.S. sales force with extraordinary marketing reach and increased relevance with primary care physicians and specialists.

The Actavis + Allergan Generics portfolio features more than 1,000 generics, branded generics, established brands and OTC products. The combined company is the third largest generic manufacturer in the U.S. and holds a top 5 leadership position in nearly 20 International markets.
Driving continued innovation and growth is the combined company’s strong commitment to R&D, with an investment of ~$1.7 billion in 2015 alone, focused on strategic development of innovative and durable value-enhancing products within brands, generics, biologics and OTC portfolios.
Learn more about this exciting combination at

Actavis Malta, has highly trained and dedicated employees, a favourable patent environment and state-of-the-art manufacturing facilities, making Malta a key contributor to the Actavis group of companies.


News Archive

Featured Products

New product

NOMARILLA® contains trans-resveratrol, Vitamin D3 and Vitamin E.

See Product leaflet for more details. 

Actavis Malta